Biocon's stock saw a price increase of 2.11% to reach Rs 336.80 during today's trading session. This movement is significant as it reflects intraday dynamics and investor response to market ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

"We welcome you to expand or relocate your businesses to our IT, IT services, AI, and data center cluster at Vizag ... withdrawal of the bill. While Biocon's Kiran Mazumdar-Shaw sought a caveat ...

May 8, 2025 India's Biocon posts higher quarterly profit on boost from generics, biosimilar business Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong ...

Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive ...

Biocon in its consolidated financial results for the fiscal fourth quarter registered Rs. 4,454 crore up by 15 per cent after adjusting FY24 revenue for BFI revenue, divestment gain and licensing ...

Biocon remains bullish on its market share prospects in the US, supported by over 70 per cent market access with payers and healthcare providers, said Matthew Erick, Chief Commercial Officer ...

Pharma major Biocon says its businesses are at a promising inflection point, with strong momentum expected to continue. “We are at a stage where all our business segments are positioned for ...

BENGALURU, India, April 28, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), today ...